This Week’s CGT News: Base Editing Takes Aim at Cholesterol

1

VERVE-102 is a one-time base editing therapy that inactivates PCSK9, showing significant cholesterol reduction in a phase 1 study.
2

The therapy produced up to 88% reduction in PCSK9 and 62% reduction in LDL-C, with effects lasting over a year in some participants.
3

Eli Lilly acquired Engage Bio to enhance its genetic medicines portfolio with non-viral DNA delivery technologies.
4

Korecyte Bio is developing a tumour-activated CAR-T therapy platform aimed at improving treatment for solid cancers.
5

Scribe Therapeutics has received clearance for a first-in-human study of STX-1150, a CRISPR-based therapy targeting PCSK9.